company background image
4530

Hisamitsu PharmaceuticalTSE:4530 Stock Report

Market Cap

JP¥318.0b

7D

-1.5%

1Y

-37.1%

Updated

07 Dec, 2021

Data

Company Financials +
4530 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance1/6
Financial Health6/6
Dividends4/6

4530 Stock Overview

Hisamitsu Pharmaceutical Co., Inc. engages in the research and development, manufacture, purchase, and sale of pharmaceuticals in Japan.

Hisamitsu Pharmaceutical Competitors

Johnson & Johnson

NYSE:JNJ

US$430.1b

Novartis

SWX:NOVN

CHF167.4b

GlaxoSmithKline

LSE:GSK

UK£78.9b

3M

NYSE:MMM

US$101.7b

Price History & Performance

Summary of all time highs, changes and price drops for Hisamitsu Pharmaceutical
Historical stock prices
Current Share PriceJP¥3,890.00
52 Week HighJP¥7,750.00
52 Week LowJP¥3,790.00
Beta0.66
1 Month Change0.78%
3 Month Change-14.22%
1 Year Change-37.06%
3 Year Change-45.29%
5 Year Change-28.49%
Change since IPO782.09%

Recent News & Updates

Shareholder Returns

4530JP PharmaceuticalsJP Market
7D-1.5%-1.9%0.7%
1Y-37.1%-11.9%9.3%

Return vs Industry: 4530 underperformed the JP Pharmaceuticals industry which returned -11.9% over the past year.

Return vs Market: 4530 underperformed the JP Market which returned 9.3% over the past year.

Price Volatility

Is 4530's price volatile compared to industry and market?
4530 volatility
4530 Average Weekly Movement4.3%
Pharmaceuticals Industry Average Movement3.9%
Market Average Movement4.1%
10% most volatile stocks in JP Market8.0%
10% least volatile stocks in JP Market2.2%

Stable Share Price: 4530 is not significantly more volatile than the rest of JP stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 4530's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
18472,770Hirotaka Nakatomihttps://www.hisamitsu.co.jp

Hisamitsu Pharmaceutical Co., Inc. engages in the research and development, manufacture, purchase, and sale of pharmaceuticals in Japan. The company provides analgesic / anti-inflammatory patches; athlete's foot / ringworm remedy products; allergy-only rhinitis drugs; eye drops; high cholesterol improving drugs; acne remedies; cooling sheets; and supporters for knee, waist, elbow, calf and ankle. It also provides cooling sprays; bactericidal antibacterial spray and deodorant spray; ship fixing sheet; adhesive plasters for magnetic products; skin care products; sweat sheet; massage roller gel and oil spray; thermal equipment, and dietary supplements.

Hisamitsu Pharmaceutical Fundamentals Summary

How do Hisamitsu Pharmaceutical's earnings and revenue compare to its market cap?
4530 fundamental statistics
Market CapJP¥317.96b
Earnings (TTM)JP¥10.56b
Revenue (TTM)JP¥120.14b

30.1x

P/E Ratio

2.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4530 income statement (TTM)
RevenueJP¥120.14b
Cost of RevenueJP¥48.88b
Gross ProfitJP¥71.26b
ExpensesJP¥60.70b
EarningsJP¥10.56b

Last Reported Earnings

Aug 31, 2021

Next Earnings Date

Jan 13, 2022

Earnings per share (EPS)129.18
Gross Margin59.31%
Net Profit Margin8.79%
Debt/Equity Ratio0.5%

How did 4530 perform over the long term?

See historical performance and comparison

Dividends

2.2%

Current Dividend Yield

65%

Payout Ratio

Does 4530 pay a reliable dividends?

See 4530 dividend history and benchmarks
When do you need to buy 4530 by to receive an upcoming dividend?
Hisamitsu Pharmaceutical dividend dates
Ex Dividend DateFeb 25 2022
Dividend Pay DateMay 28 2022
Days until Ex dividend79 days
Days until Dividend pay date171 days

Does 4530 pay a reliable dividends?

See 4530 dividend history and benchmarks

Valuation

Is Hisamitsu Pharmaceutical undervalued compared to its fair value and its price relative to the market?

49.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 4530 (¥3890) is trading below our estimate of fair value (¥7678.8)

Significantly Below Fair Value: 4530 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 4530 is poor value based on its PE Ratio (30.1x) compared to the JP Pharmaceuticals industry average (18.1x).

PE vs Market: 4530 is poor value based on its PE Ratio (30.1x) compared to the JP market (13x).


Price to Earnings Growth Ratio

PEG Ratio: 4530 is poor value based on its PEG Ratio (1.6x)


Price to Book Ratio

PB vs Industry: 4530's PB Ratio (1.2x) is in line with the JP Pharmaceuticals industry average.


Future Growth

How is Hisamitsu Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

18.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4530's forecast earnings growth (18.8% per year) is above the savings rate (0.02%).

Earnings vs Market: 4530's earnings (18.8% per year) are forecast to grow faster than the JP market (10.3% per year).

High Growth Earnings: 4530's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4530's revenue (7.5% per year) is forecast to grow faster than the JP market (4.9% per year).

High Growth Revenue: 4530's revenue (7.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 4530's Return on Equity is forecast to be low in 3 years time (7.4%).


Past Performance

How has Hisamitsu Pharmaceutical performed over the past 5 years?

-10.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4530 has high quality earnings.

Growing Profit Margin: 4530's current net profit margins (8.8%) are lower than last year (11.4%).


Past Earnings Growth Analysis

Earnings Trend: 4530's earnings have declined by 10.8% per year over the past 5 years.

Accelerating Growth: 4530's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4530 had negative earnings growth (-28.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.3%).


Return on Equity

High ROE: 4530's Return on Equity (4.1%) is considered low.


Financial Health

How is Hisamitsu Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: 4530's short term assets (¥206.1B) exceed its short term liabilities (¥31.7B).

Long Term Liabilities: 4530's short term assets (¥206.1B) exceed its long term liabilities (¥17.3B).


Debt to Equity History and Analysis

Debt Level: 4530 has more cash than its total debt.

Reducing Debt: 4530's debt to equity ratio has reduced from 1% to 0.5% over the past 5 years.

Debt Coverage: 4530's debt is well covered by operating cash flow (1157.2%).

Interest Coverage: 4530 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Hisamitsu Pharmaceutical current dividend yield, its reliability and sustainability?

2.16%

Current Dividend Yield


Upcoming Dividend Payment

TodayDec 08 2021Ex Dividend DateFeb 25 2022Dividend Pay DateMay 28 202292 days from Ex DividendBuy in the next 79 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 4530's dividend (2.16%) is higher than the bottom 25% of dividend payers in the JP market (1.43%).

High Dividend: 4530's dividend (2.16%) is low compared to the top 25% of dividend payers in the JP market (3.3%).


Stability and Growth of Payments

Stable Dividend: 4530's dividends per share have been stable in the past 10 years.

Growing Dividend: 4530's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (64.8%), 4530's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

JP¥173m

CEO Compensation


CEO

Hirotaka Nakatomi

no data

Tenure

JP¥173,000,000

Compensation

Mr. Hirotaka Nakatomi serves as the Chief Executive Officer of Hisamitsu Pharmaceutical Co. Inc. Mr. Nakatomi served as the President of Hisamitsu Pharmaceutical Co. Inc. Mr. Nakatomi serves as the Chairma...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Hirotaka's total compensation is reasonable compared to companies of similar size in the JP market.

Compensation vs Earnings: Hirotaka's compensation has been consistent with company performance over the past year.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Hisamitsu Pharmaceutical Co., Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Hisamitsu Pharmaceutical Co., Inc.
  • Ticker: 4530
  • Exchange: TSE
  • Founded: 1847
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: JP¥317.961b
  • Shares outstanding: 81.74m
  • Website: https://www.hisamitsu.co.jp

Number of Employees


Location

  • Hisamitsu Pharmaceutical Co., Inc.
  • 408, Tashiro Daikan-machi
  • Tosu
  • Saga
  • 841-0017
  • Japan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/07 15:58
End of Day Share Price2021/12/07 00:00
Earnings2021/08/31
Annual Earnings2021/02/28


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.